{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:00:44Z","timestamp":1781089244071,"version":"3.54.1"},"posted":{"date-parts":[[2026,6,10]]},"group-title":"In Review","reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,7]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a restrictive cardiac disease caused by the deposition of TTR in the heart. TTR is synthesized by hepatocytes and circulates as a homotetramer carrying complex for thyroxine and retinol. Mutations in TTR destabilize the tetramer promoting its dissociation into monomers that can enter the heart and aggregate into amyloid fibrils driving cytotoxicity, fibrosis, impaired electrical conductivity, and progressive cardiac dysfunction. Mechanistic studies and therapeutic development have been limited by the lack of physiologically relevant human preclinical models. Here we describe the creation of two\n                  <italic>in vitro<\/italic>\n                  models of ATTR-CM using human iPSC-derived cells. First, a custom microphysiological chip containing co-cultured hepatic and cardiac organoids in isolated chambers connected by microchannels enabling free passage, including hepatocyte synthesized TTR\n                  <sup>122VI<\/sup>\n                  , which diffuses to and is taken up by cardiac organoids recapitulating pathologic hepatic-cardiac crosstalk. Cardiac organoids exposed to TTR\n                  <sup>V122I<\/sup>\n                  exhibited increased oxidative stress, elevated cytotoxicity, and upregulation of fibronectin. Second, engineered heart tissues cultured with monomeric TTR\n                  <sup>V122I<\/sup>\n                  demonstrated TTR uptake, reduced contractility, and prolonged relaxation time that mirrors cardiac dysfunction observed clinically. These novel human-based models recapitulate key biochemical, cellular, and functional features of ATTR-CM, providing translational platforms to elucidate disease mechanisms and evaluate novel therapeutic strategies.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9636540\/v1","type":"posted-content","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:06:22Z","timestamp":1781085982000},"source":"Crossref","is-referenced-by-count":0,"title":["Development of Human iPSC-based Microphysiogical Models of Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.21203","author":[{"given":"Marcus A.C.","family":"Williams","sequence":"first","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junseong","family":"Park","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atharva R.","family":"Mulay","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Mair","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colton R.","family":"Lysaker","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Jani","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desirae","family":"McKoy","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Rhodehamel","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisha","family":"Garg","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Wu","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Koilada","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharanya","family":"Parvathaneni","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lin","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Wilkins","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sharma","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joban","family":"Vaishnav","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Ranek","sequence":"additional","affiliation":[{"name":"The Johns Hopkins Medical Institutions"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg FL","year":"2019","unstructured":"Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W. & Maurer, M. S. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 73, 2872\u20132891. 10.1016\/j.jacc.2019.04.003 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/13506129.2024.2398446","article-title":"International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction","volume":"31","author":"Yun S","year":"2024","unstructured":"Yun, S. et al. International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction. Amyloid 31, 291\u2013301. 10.1080\/13506129.2024.2398446 (2024).","journal-title":"Amyloid"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis","volume":"128","author":"Griffin JM","year":"2021","unstructured":"Griffin, J. M., Rosenblum, H. & Maurer, M. S. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circ. Res. 128, 1554\u20131575. 10.1161\/CIRCRESAHA.121.318187 (2021).","journal-title":"Circ. Res."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction","author":"AbouEzzeddine OF","year":"2021","unstructured":"AbouEzzeddine, O. F. et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 10.1001\/jamacardio.2021.3070 (2021).","journal-title":"JAMA Cardiol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore JD","year":"2016","unstructured":"Gillmore, J. D. et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 133, 2404\u20132412. 10.1161\/CIRCULATIONAHA.116.021612 (2016).","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"46181","DOI":"10.31083\/RCM46181","article-title":"Transthyretin Cardiac Amyloidosis and Heart Failure: State-of-the-Art Review and Practice Guidance","volume":"26","author":"Bukhari S","year":"2025","unstructured":"Bukhari, S., Hamza, M. & Malik, A. Transthyretin Cardiac Amyloidosis and Heart Failure: State-of-the-Art Review and Practice Guidance. Rev. Cardiovasc. Med. 26, 46181. 10.31083\/RCM46181 (2025).","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum JN","year":"2017","unstructured":"Buxbaum, J. N. & Ruberg, F. L. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet. Med. 19, 733\u2013742. 10.1038\/gim.2016.200 (2017).","journal-title":"Genet. Med."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11897-024-00669-7","article-title":"Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment","volume":"21","author":"Vogel J","year":"2024","unstructured":"Vogel, J. et al. Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment. Curr. Heart Fail. Rep. 21, 305\u2013321. 10.1007\/s11897-024-00669-7 (2024).","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl. J. Med. 379, 1007\u20131016. 10.1056\/NEJMoa1805689 (2018).","journal-title":"N Engl. J. Med."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.04.008","article-title":"Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B","author":"Witteles RM","year":"2025","unstructured":"Witteles, R. M. et al. Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. J. Am. Coll. Cardiol. 10.1016\/j.jacc.2025.04.008 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e103843","DOI":"10.7759\/cureus.103843","article-title":"Advances in the Diagnosis and Disease-Modifying Management of Transthyretin Amyloid Cardiomyopathy: A Narrative Review","volume":"18","author":"Vijaykumar V","year":"2026","unstructured":"Vijaykumar, V. Advances in the Diagnosis and Disease-Modifying Management of Transthyretin Amyloid Cardiomyopathy: A Narrative Review. Cureus 18, e103843. 10.7759\/cureus.103843 (2026).","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1016\/j.febslet.2009.07.031","article-title":"Animal models of human amyloidoses: are transgenic mice worth the time and trouble?","volume":"583","author":"Buxbaum JN","year":"2009","unstructured":"Buxbaum, J. N. Animal models of human amyloidoses: are transgenic mice worth the time and trouble? FEBS Lett. 583, 2663\u20132673. 10.1016\/j.febslet.2009.07.031 (2009).","journal-title":"FEBS Lett."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/cvr\/cvaf152","article-title":"In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential","volume":"121","author":"Qin J","year":"2025","unstructured":"Qin, J. et al. In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential. Cardiovasc. Res. 121, 1997\u20132013. 10.1093\/cvr\/cvaf152 (2025).","journal-title":"Cardiovasc. Res."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.stemcr.2013.10.003","article-title":"Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis","volume":"1","author":"Leung A","year":"2013","unstructured":"Leung, A. et al. Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis. Stem Cell. Rep. 1, 451\u2013463. 10.1016\/j.stemcr.2013.10.003 (2013).","journal-title":"Stem Cell. Rep."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.stemcr.2020.07.003","article-title":"Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease","volume":"15","author":"Giadone RM","year":"2020","unstructured":"Giadone, R. M. et al. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease. Stem Cell. Rep. 15, 515\u2013528. 10.1016\/j.stemcr.2020.07.003 (2020).","journal-title":"Stem Cell. Rep."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2018.1489228","article-title":"A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics","volume":"25","author":"Giadone RM","year":"2018","unstructured":"Giadone, R. M. et al. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid 25, 148\u2013155. 10.1080\/13506129.2018.1489228 (2018).","journal-title":"Amyloid"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20140155","article-title":"Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage","volume":"35","author":"Manral P","year":"2015","unstructured":"Manral, P. & Reixach, N. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. Biosci. Rep. 35 10.1042\/BSR20140155 (2015).","journal-title":"Biosci. Rep."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd12110434","article-title":"Human-Induced Pluripotent Stem Cell Models for Amyloid Cardiomyopathy: From Mechanistic Insights to Therapeutic Discovery","volume":"12","author":"Liu Y","year":"2025","unstructured":"Liu, Y. & Riaz, M. Human-Induced Pluripotent Stem Cell Models for Amyloid Cardiomyopathy: From Mechanistic Insights to Therapeutic Discovery. J. Cardiovasc. Dev. Dis. 12 10.3390\/jcdd12110434 (2025).","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamacardio.2020.5969","article-title":"Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population","volume":"6","author":"Greve AM","year":"2021","unstructured":"Greve, A. M., Christoffersen, M., Frikke-Schmidt, R., Nordestgaard, B. G. & Tybjaerg-Hansen, A. Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population. JAMA Cardiol. 6, 258\u2013266. 10.1001\/jamacardio.2020.5969 (2021).","journal-title":"JAMA Cardiol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e004000","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin","volume":"11","author":"Hanson JLS","year":"2018","unstructured":"Hanson, J. L. S. et al. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ. Heart Fail. 11, e004000. 10.1161\/CIRCHEARTFAILURE.117.004000 (2018).","journal-title":"Circ. Heart Fail."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s44161-022-00200-y","article-title":"Surfaceome mapping of primary human heart cells with CellSurfer uncovers cardiomyocyte surface protein LSMEM2 and proteome dynamics in failing hearts","volume":"2","author":"Luecke LB","year":"2023","unstructured":"Luecke, L. B. et al. Surfaceome mapping of primary human heart cells with CellSurfer uncovers cardiomyocyte surface protein LSMEM2 and proteome dynamics in failing hearts. Nat. Cardiovasc. Res. 2, 76\u201395. 10.1038\/s44161-022-00200-y (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12112601","article-title":"Adipocyte-Mediated Electrophysiological Remodeling of PKP-2 Mutant Human Pluripotent Stem Cell-Derived Cardiomyocytes","volume":"12","author":"Morrissette-McAlmon J","year":"2024","unstructured":"Morrissette-McAlmon, J. et al. Adipocyte-Mediated Electrophysiological Remodeling of PKP-2 Mutant Human Pluripotent Stem Cell-Derived Cardiomyocytes. Biomedicines 12 10.3390\/biomedicines12112601 (2024).","journal-title":"Biomedicines"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.yjmcc.2024.02.002","article-title":"Adipocyte-mediated electrophysiological remodeling of human stem cell - derived cardiomyocytes","volume":"189","author":"Morrissette-McAlmon J","year":"2024","unstructured":"Morrissette-McAlmon, J., Xu, W. R., Teuben, R., Boheler, K. R. & Tung, L. Adipocyte-mediated electrophysiological remodeling of human stem cell - derived cardiomyocytes. J. Mol. Cell. Cardiol. 189, 52\u201365. 10.1016\/j.yjmcc.2024.02.002 (2024).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/01.res.0000027865.61704.32","article-title":"Differentiation of pluripotent embryonic stem cells into cardiomyocytes","volume":"91","author":"Boheler KR","year":"2002","unstructured":"Boheler, K. R. et al. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ. Res. 91, 189\u2013201. 10.1161\/01.res.0000027865.61704.32 (2002).","journal-title":"Circ. Res."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1385\/1-59259-241-4:127","article-title":"Embryonic stem cells as a model to study cardiac, skeletal muscle, and vascular smooth muscle cell differentiation","volume":"185","author":"Wobus AM","year":"2002","unstructured":"Wobus, A. M., Guan, K., Yang, H. T. & Boheler, K. R. Embryonic stem cells as a model to study cardiac, skeletal muscle, and vascular smooth muscle cell differentiation. Methods Mol. Biol. 185, 127\u2013156. 10.1385\/1-59259-241-4:127 (2002).","journal-title":"Methods Mol. Biol."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/9780470151808.sc01g04s26","author":"Mallanna SK","year":"2013","unstructured":"Mallanna, S. K. & Duncan, S. A. Differentiation of hepatocytes from pluripotent stem cells. Curr Protoc Stem Cell Biol. ;26:1G 4 1-1G 4 13. (2013). 10.1002\/9780470151808.sc01g04s26"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10544-005-6070-2","article-title":"Characterization of polydimethylsiloxane (PDMS) properties for biomedical micro\/nanosystems","volume":"7","author":"Mata A","year":"2005","unstructured":"Mata, A., Fleischman, A. J. & Roy, S. Characterization of polydimethylsiloxane (PDMS) properties for biomedical micro\/nanosystems. Biomed. Microdevices. 7, 281\u2013293. 10.1007\/s10544-005-6070-2 (2005).","journal-title":"Biomed. Microdevices"},{"key":"ref28","author":"Xia Y","year":"1998","unstructured":"Xia, Y. & Whitesides, G. M. Soft Lithography. Angew Chem Int Ed Engl. ;37:550\u2013575. doi: 10.1002\/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G (1998)."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1039\/d1lc00348h","article-title":"Simulating drug concentrations in PDMS microfluidic organ chips","volume":"21","author":"Grant J","year":"2021","unstructured":"Grant, J. et al. Simulating drug concentrations in PDMS microfluidic organ chips. Lab. Chip. 21, 3509\u20133519. 10.1039\/d1lc00348h (2021).","journal-title":"Lab. Chip"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"CIR0000000000000792","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","author":"Kittleson MM","year":"2020","unstructured":"Kittleson, M. M. et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation CIR0000000000000792. 10.1161\/CIR.0000000000000792 (2020).","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"101271","DOI":"10.1016\/j.jacbts.2025.03.003","article-title":"Myocardium From Patients With ATTR Amyloidosis Produces Less Force Secondary to Increased Fibrosis","volume":"10","author":"Milburn GN","year":"2025","unstructured":"Milburn, G. N. et al. Myocardium From Patients With ATTR Amyloidosis Produces Less Force Secondary to Increased Fibrosis. JACC Basic. Transl Sci. 10, 101271. 10.1016\/j.jacbts.2025.03.003 (2025).","journal-title":"JACC Basic. Transl Sci."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9636540\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9636540\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:06:27Z","timestamp":1781085987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9636540\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":31,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9636540\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,6,10]]},"subtype":"preprint"}}